Perceptive Advisors - Q1 2019 holdings

$3.54 Billion is the total value of Perceptive Advisors's 105 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 57.4% .

 Value Shares↓ Weighting
NBIX SellNEUROCRINE BIOSCIENCES INC$331,138,000
+5.0%
3,758,662
-18.4%
9.34%
-22.2%
FOLD BuyAMICUS THERAPEUTICS INC$294,297,000
+53.5%
21,639,486
+4.4%
8.30%
+13.8%
GBT BuyGLOBAL BLOOD THERAPEUTICS INC$292,476,000
+31.3%
5,525,726
+1.8%
8.25%
-2.6%
ZGNX BuyZOGENIX INC$212,860,000
+54.0%
3,869,491
+2.1%
6.01%
+14.2%
AMRN BuyAMARIN CORPORATION PLCspons adr new$135,790,000
+110.4%
6,540,957
+34.2%
3.83%
+55.9%
ASND BuyASCENDIS PHARMA A Ssponsored adr$131,039,000
+107.9%
1,113,328
+5.8%
3.70%
+54.1%
IOVA SellIOVANCE BIOTHERAPEUTICS INC$116,362,000
+7.4%
12,235,811
-0.0%
3.28%
-20.4%
MGTX BuyMEIRAGTX HOLDINGS PLC$103,513,000
+128.3%
6,007,746
+27.7%
2.92%
+69.2%
ARRY NewARRAY BIOPHARMA INC$103,101,0004,228,900
+100.0%
2.91%
BPMC BuyBLUEPRINT MEDICINES CORP$101,748,000
+134.0%
1,271,054
+48.3%
2.87%
+73.5%
QTNT  QUOTIENT LTD$97,209,000
+47.2%
10,789,0540.0%2.74%
+9.2%
MRTX BuyMIRATI THERAPEUTICS INC$85,349,000
+1525.7%
1,164,382
+825.0%
2.41%
+1104.0%
RTRX SellRETROPHIN INC$69,128,000
+38.9%
3,054,707
-8.6%
1.95%
+2.9%
RGNX BuyREGENXBIO INC$65,662,000
+144.2%
1,145,726
+77.4%
1.85%
+81.0%
MMSI BuyMERIT MEDICAL SYSTEMS INC$65,113,000
+24.8%
1,053,098
+10.9%
1.84%
-7.5%
ARNA SellARENA PHARMACEUTICALS INC$62,770,000
+12.9%
1,400,171
-2.1%
1.77%
-16.3%
ATNX  ATHENEX INC$62,426,000
+91.8%
5,096,0220.0%1.76%
+42.1%
CRNX  CRINETICS PHARMACEUTICALS INC$58,901,000
-24.1%
2,587,9530.0%1.66%
-43.7%
CBAY BuyCYMABAY THERAPEUTICS INC$55,946,000
+188.6%
4,212,821
+71.1%
1.58%
+113.8%
ALBO  ALBIREO PHARMA INC$54,896,000
+39.0%
1,704,3300.0%1.55%
+3.0%
MYOK SellMYOKARDIA INC$51,393,000
-3.9%
988,511
-8.1%
1.45%
-28.8%
NVTA BuyINVITAE CORP$50,866,000
+146.8%
2,171,918
+16.6%
1.44%
+83.0%
ALLO  ALLOGENE THERAPEUTICS INC$44,630,000
+7.4%
1,543,7900.0%1.26%
-20.4%
VBIV  VBI VACCINES INC$42,633,000
+11.2%
23,951,5560.0%1.20%
-17.5%
MNTA BuyMOMENTA PHARMACEUTICALS INC$41,774,000
+34.2%
2,875,000
+1.8%
1.18%
-0.5%
VRCA  VERRICA PHARMACEUTICALS INC$38,537,000
+38.7%
3,410,4120.0%1.09%
+2.7%
NewSOLID BIOSCIENCES INC$36,130,0003,927,222
+100.0%
1.02%
VRAY BuyVIEWRAY INC$35,514,000
+63.5%
4,805,650
+23.0%
1.00%
+21.3%
KDMN  KADMON HOLDINGS INC$34,757,000
+26.9%
13,165,7460.0%0.98%
-5.9%
CTMX BuyCYTOMX THERAPEUTICS INC$34,120,000
-21.7%
3,173,923
+9.0%
0.96%
-42.0%
NEPT  NEPTUNE WELLNESS SOLUTIONS INC$28,363,000
+58.9%
8,891,4520.0%0.80%
+17.8%
ALDX  ALDEYRA THERAPEUTICS INC$27,862,000
+12.9%
3,085,4580.0%0.79%
-16.3%
DOVA  DOVA PHARMACEUTICALS INC$27,788,000
+17.3%
3,125,8510.0%0.78%
-13.1%
TDOC BuyTELADOC HEALTH INC$27,522,000
+825.4%
495,000
+725.0%
0.78%
+587.6%
CNCE BuyCONCERT PHARMACEUTICALS INC$26,610,000
+16.6%
2,204,641
+17.7%
0.75%
-13.6%
NVRO NewNEVRO CORP$26,063,000416,949
+100.0%
0.74%
BuyPROTAGONIST THERAPEUTICS INC$26,036,000
+183.3%
2,071,297
+51.7%
0.74%
+110.0%
ADMA  ADMA BIOLOGICS INC$24,715,000
+70.0%
6,521,1020.0%0.70%
+26.0%
VAPO BuyVAPOTHERM INC$24,490,000
+0.1%
1,246,315
+1.6%
0.69%
-25.8%
KOD  KODIAK SCIENCES INC$20,472,000
-8.0%
3,135,1990.0%0.58%
-31.8%
EHTH BuyEHEALTH INC$18,070,000
+755.2%
289,857
+426.8%
0.51%
+537.5%
FOMX  FOAMIX PHARMACEUTICALS LTD$17,482,000
+10.3%
4,661,8240.0%0.49%
-18.2%
AXNX SellAXONICS MODULATION TECHNOLOGIES INC$16,424,000
+50.2%
685,756
-8.7%
0.46%
+11.3%
EIDX BuyEIDOS THERAPEUTICS INC$16,109,000
+70.4%
686,992
+0.0%
0.46%
+26.4%
IRTC NewIRHYTHM TECHNOLOGIES INC$14,992,000200,000
+100.0%
0.42%
BHC NewBAUSCH HEALTH COS INC$14,820,000600,000
+100.0%
0.42%
ESTA  ESTABLISHMENT LABS HLDGS INC$14,766,000
-7.0%
614,2420.0%0.42%
-31.0%
 AQUESTIVE THERAPEUTICS INC$14,603,000
+9.7%
2,113,4000.0%0.41%
-18.7%
AKBA  AKEBIA THERAPEUTICS INC$13,951,000
+51.9%
1,703,4400.0%0.39%
+12.9%
QURE BuyUNIQURE NV.$13,828,000
+132.6%
231,820
+5.0%
0.39%
+72.6%
RYTM SellRHYTHM PHARMACEUTICALS INC$13,786,000
+0.2%
502,970
-1.2%
0.39%
-25.8%
MEIP  MEI PHARMA INC$13,509,000
+16.3%
4,400,4400.0%0.38%
-13.8%
MRKR  MARKER THERAPEUTICS INC$13,200,000
+18.9%
2,000,0000.0%0.37%
-11.8%
AGRX NewAGILE THERAPEUTICS INC$12,724,0008,426,750
+100.0%
0.36%
MOTS  MOTUS GI HLDGS INC$12,521,000
+25.4%
3,210,5420.0%0.35%
-7.1%
MTEM  MOLECULAR TEMPLATES INC$11,470,000
+61.4%
1,974,1330.0%0.32%
+20.0%
PRQR  PROQR THERAPEUTICS N.V.$10,021,000
-10.9%
722,5230.0%0.28%
-33.9%
ALEC NewALECTOR INC$9,579,000511,731
+100.0%
0.27%
ORTX  ORCHARD THERAPEUTICS PLCads$9,329,000
+13.7%
521,8000.0%0.26%
-15.7%
HUM NewHUMANA INC$9,310,00035,000
+100.0%
0.26%
DBVT BuyDBV TECHNOLOGIES S Asponsored adr$8,700,000
+63.9%
1,128,524
+36.5%
0.24%
+21.3%
UROV BuyUROVANT SCIENCES LTD$8,697,000
+122.1%
865,359
+38.4%
0.24%
+64.4%
ZYME  ZYMEWORKS INC$8,529,000
+18.5%
573,8900.0%0.24%
-12.0%
 ANI PHARMACEUTICALS INCnote 3.000%12/0$8,239,000
+11.6%
7,500,0000.0%0.23%
-17.4%
RCKT BuyROCKET PHARMACEUTICALS INC$8,036,000
+129.9%
458,173
+90.8%
0.23%
+70.7%
SYBX  SYNLOGIC INC$6,587,000
+8.9%
867,8520.0%0.19%
-19.1%
ARWR BuyARROWHEAD PHARMACEUTICALS INC$6,069,000
+69.4%
330,738
+10.2%
0.17%
+25.7%
SWAV NewSHOCKWAVE MEDICAL INC$5,021,000150,000
+100.0%
0.14%
SRRA  SIERRA ONCOLOGY INC$4,559,000
+33.6%
2,666,1900.0%0.13%
-0.8%
TBIO  TRANSLATE BIO INC$4,433,000
+40.0%
435,0000.0%0.12%
+3.3%
LIVN NewLIVANOVA PLC$3,890,00040,000
+100.0%
0.11%
RARE NewULTRAGENYX PHARMACEUTICAL INC$3,468,00050,000
+100.0%
0.10%
XENT NewINTERSECT ENT INC$2,251,00070,000
+100.0%
0.06%
VERU  VERU INC$2,081,000
+12.3%
1,425,0000.0%0.06%
-16.9%
EIGR  EIGER BIOPHARMACEUTICALS INC$1,955,000
+37.6%
139,8900.0%0.06%
+1.9%
ABEOW  ABEONA THERAPEUTICS INC*w exp 12/24/201$1,906,000
+50.4%
659,6360.0%0.05%
+12.5%
ACST  ACASTI PHARMA INCcl a new$1,815,000
+22.6%
1,779,8820.0%0.05%
-8.9%
OMED  ONCOMED PHARMACEUTICALS INC$1,787,000
+39.2%
1,719,1110.0%0.05%
+2.0%
VCRA NewVOCERA COMMUNICATIONS INC$1,582,00050,000
+100.0%
0.04%
CRY NewCRYOLIFE INC$1,459,00050,000
+100.0%
0.04%
ABEO  ABEONA THERAPEUTICS INC$1,331,000
+4.9%
180,7970.0%0.04%
-20.8%
AVDR NewAVEDRO INC$1,227,000100,000
+100.0%
0.04%
ALNA  ALLENA PHARMACEUTICALS INC$929,000
+32.0%
132,3000.0%0.03%
-3.7%
NewFIAT CHRYSLER AUTOMOBILES N$920,00062,000
+100.0%
0.03%
RACE  FERRARI N.V.$830,000
+36.1%
6,2000.0%0.02%0.0%
TNDM  TANDEM DIABETES CARE INC$816,000
+70.4%
12,8440.0%0.02%
+27.8%
VCYT NewVERACYTE INC$789,00031,521
+100.0%
0.02%
AXSM NewAXSOME THERAPEUTICS INC$767,00053,879
+100.0%
0.02%
CLVS NewCLOVIS ONCOLOGY INCput$660,000200,000
+100.0%
0.02%
BIIB NewBIOGEN INCcall$620,000400,000
+100.0%
0.02%
FLDM NewFLUIDIGM CORP$612,00046,030
+100.0%
0.02%
FGEN NewFIBROGEN INC$506,0009,306
+100.0%
0.01%
VCEL  VERICEL CORP$492,000
+0.8%
28,0900.0%0.01%
-26.3%
SRPT NewSAREPTA THERAPEUTICS INCcall$421,000100,000
+100.0%
0.01%
ACAD NewACADIA PHARMACEUTICALS INC$400,00014,897
+100.0%
0.01%
BEAT NewBIOTELEMETRY INC$399,0006,369
+100.0%
0.01%
EOLS NewEVOLUS INC$344,00015,232
+100.0%
0.01%
AGIO NewAGIOS PHARMACEUTICALS INCcall$140,000200,000
+100.0%
0.00%
CLVS NewCLOVIS ONCOLOGY INCcall$125,000200,000
+100.0%
0.00%
OTLKW  OUTLOOK THERAPEUTICS INC*w exp 02/18/202$159,000
+120.8%
420,8750.0%0.00%
+33.3%
IMMU  IMMUNOMEDICS INCcall$125,000
-59.4%
200,0000.0%0.00%
-66.7%
NewSOLID BIOSCIENCES INCcall$29,00010,000
+100.0%
0.00%
ASND NewASCENDIS PHARMA A Sput$25,000200,000
+100.0%
0.00%
ONCS SellONCOSEC MEDICAL INC$17,000
-46.9%
30,000
-40.0%
0.00%
-100.0%
IMGN NewIMMUNOGEN INCcall$15,000600,000
+100.0%
0.00%
SLDB ExitSOLID BIOSCIENCES INCcall$0-1,835
-100.0%
-0.00%
VCNX ExitVACCINEX INC$0-50,000
-100.0%
-0.01%
ALQA ExitALLIQUA BIOMEDICAL INC$0-114,730
-100.0%
-0.01%
SIBN ExitSI-BONE INC$0-15,000
-100.0%
-0.01%
STAA ExitSTAAR SURGICAL CO$0-12,953
-100.0%
-0.02%
AMED ExitAMEDISYS INC$0-3,672
-100.0%
-0.02%
GKOS ExitGLAUKOS CORP$0-7,466
-100.0%
-0.02%
ZGNX ExitZOGENIX INCput$0-200,000
-100.0%
-0.02%
DXCM ExitDEXCOM INC$0-3,733
-100.0%
-0.02%
ExitPERNIX THERAPEUTICS HLDGS INdbcv 4,250% 4/0$0-1,000,000
-100.0%
-0.02%
IVC ExitINVACARE CORP$0-200,000
-100.0%
-0.03%
FCAU ExitFIAT CHRYSLER AUTOMOBILES N.$0-62,000
-100.0%
-0.03%
ADVM ExitADVERUM BIOTECHNOLOGIES INC$0-300,000
-100.0%
-0.04%
CDNA ExitCAREDX INC$0-44,128
-100.0%
-0.04%
PEN ExitPENUMBRA INC$0-16,338
-100.0%
-0.08%
WVE ExitWAVE LIFE SCIENCES LTD$0-59,498
-100.0%
-0.10%
TXMD ExitTHERAPEUTICSMD INC$0-1,500,000
-100.0%
-0.22%
XNCR ExitXENCOR INC$0-196,810
-100.0%
-0.26%
COLL ExitCOLLEGIUM PHARMACEUTICAL INC$0-445,000
-100.0%
-0.28%
IMMU ExitIMMUNOMEDICS INC$0-700,000
-100.0%
-0.40%
SAGE ExitSAGE THERAPEUTICS INC$0-147,315
-100.0%
-0.50%
CMTA ExitCLEMENTIA PHARMACEUTICALS INC$0-1,500,000
-100.0%
-0.67%
ALNY ExitALNYLAM PHARMACEUTICALS INC$0-262,241
-100.0%
-0.70%
XLRN ExitACCELERON PHARMA INC$0-905,017
-100.0%
-1.52%
LJPC ExitLA JOLLA PHARMACEUTICAL CO$0-4,313,611
-100.0%
-1.56%
ARGX ExitARGENX SEsponsored adr$0-560,941
-100.0%
-2.05%
SLDB ExitSOLID BIOSCIENCES INC$0-3,927,222
-100.0%
-4.01%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2019-05-16
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q1 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-04-17
SC 13D/A2024-04-17
42024-04-15
SC 13G/A2024-04-15
SC 13G2024-04-15
SC 13D/A2024-04-10
42024-04-08
42024-04-03
SC 13D/A2024-04-03
SC 13D2024-03-20

View Perceptive Advisors's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported has been restated
  • The reported has been amended

Export Perceptive Advisors's holdings